Skip to main content

Mintz Advises Cardurion Pharmaceuticals in Investment of up to $300 Million from Bain Capital

Mintz advised Cardurion Pharmaceuticals, Inc. (Cardurion), a clinical-stage biotechnology company, in a recently closed private investment of up to $300 million from Bain Capital Life Sciences and Bain Capital Private Equity. Bain Capital joins existing investors Takeda Pharmaceuticals and Polaris Partners in supporting the evolution of Cardurion into a leading cardiovascular biotechnology company. This latest investment will support the thoughtful advancement of Cardurion’s pipeline, enable the company to scale its team, and create an industry-leading platform.

Based in Boston and with facilities there and in Shonan, Japan, Cardurion is focused on the discovery and development of novel, next-generation therapeutics for the treatment of heart failure and other cardiovascular diseases. Founded by physician-scientist Michael E. Mendelsohn, M.D., and built by a team of physician-scientists and industry leaders with extensive experience in cardiovascular science, drug development, and business development, Cardurion is pursuing unique drug discovery and development programs to target major unmet needs in cardiovascular medicine. Its innovative pipeline of cardiovascular drug candidates includes a PDE9 inhibitor and a CaMKII inhibitor program. Seasoned biotech executive Peter S. Lawrence joined Cardurion as the company’s Chief Executive Officer in March 2020.

Mintz, and specifically, Member, Chair of the firm’s Securities & Capital Markets Practice, and Co-chair of the firm’s Life Sciences Practice Jonathan Kravetz, has served as legal counsel to Cardurion since the company’s inception, advising on numerous complex contractual and strategic matters. The Mintz team that advised Cardurion in the investment by Bain Capital was led by Mr. Kravetz and Member Samuel Effron and included Member Andrew Bernstein, Of Counsel Anne Bruno and Michelle Capezza, and Associates Marc Aspis, Marine Bouaziz, William Bussiere, Ilse Johnson, and Amanda Mei.

Dr. Mendelsohn commented, “Led by Jon Kravetz, the team of Mintz attorneys including Sam Effron, John Cheney, Roy Gillig, Anne Bruno, Will Bussiere, and others, has been an exceptional support and ally of Cardurion since its formation five years ago and throughout its growth to date. Mintz worked tirelessly to lead Cardurion through this complex and intricate transaction with the utmost skill and professionalism.”

Mintz is one of the leading law firms to the life sciences industry. The firm’s attorneys advise hundreds of businesses and other organizations across the sector’s ecosystem—from start-ups and emerging growth companies to large public companies as well as venture capital firms, investment banks, and research and academic institutions—on pivotal deals, mission-critical disputes, intellectual property, and regulatory matters. Learn more about Mintz’s Life Sciences Practice here.